{"product_id":"azenta-bcg-matrix","title":"Azenta Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnlock Strategic Clarity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eAzenta’s BCG Matrix preview highlights where its product lines likely sit across Stars, Cash Cows, Dogs, and Question Marks based on market share and growth signals—useful but intentionally high-level. Purchase the full BCG Matrix to get quadrant-by-quadrant placements, quantitative metrics, and actionable recommendations tailored to optimize capital allocation and product strategy. This ready-to-use report includes a detailed Word analysis plus an Excel summary so you can present findings and execute decisions quickly—buy now for instant access.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNext-Generation Sequencing Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAzenta’s Next-Generation Sequencing (NGS) services sit in the Stars quadrant: the company held ~25% market share in high-throughput sequencing services in 2024 and reported NGS-related revenue of $420M in FY2024, up 18% year-over-year as demand for genomic data in personalized medicine grows.\u003c\/p\u003e\n\u003cp\u003eAzenta has invested $160M since 2022 in automated, high-throughput sequencers and capacity expansion to fend off emerging competitors like BGI and Illumina, but sustaining leadership requires ongoing capital reinvestment as read-lengths and throughput improve rapidly.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAutomated Cryogenic Storage Systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe BioStore and B3C product lines are the gold standard for automated cryogenic sample management in pharma, with Azenta claiming roughly 35–40% share of high-density cold storage for biobanks as of 2025.\u003c\/p\u003e\n\u003cp\u003eDemand is rising: biologic drug candidates grew ~8% CAGR 2018–2024, driving a 2024 market for automated cryogenic systems estimated at $720M and projected 9% CAGR to 2029.\u003c\/p\u003e\n\u003cp\u003eAzenta’s leadership boosts margins, but heavy R\u0026amp;D—about $65M spent in 2024—compresses free cash flow and keeps next-gen automation capital-intensive.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMultiomics Data Integration Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBy combining genomic, proteomic, and clinical data, Azenta’s multiomics platform offers a comprehensive suite now used by ~28% of biotech labs surveyed in 2024, driving strong demand among drug-discovery teams.\u003c\/p\u003e\n\u003cp\u003eThe segment grew ~34% CAGR 2021–2024 as R\u0026amp;D shifts from single-gene to multi-layered biology; market forecasts project $6.2B global value by 2027.\u003c\/p\u003e\n\u003cp\u003eAzenta is aggressively expanding this portfolio—announcing a $45M software R\u0026amp;D investment in 2024—to capture share, balancing high revenue potential with heavy development costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLarge-Scale Biobanking Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAzenta’s Large-Scale Biobanking Services is a Star: revenue grew ~28% in 2024 to an estimated $215M, driven by outsourcing demand from population health studies and phase II\/III trials; the unit leverages 40+ global biorepositories to capture share as sponsors cut internal lab footprints.\u003c\/p\u003e\n\u003cp\u003eIt’s a primary growth driver but capital-intensive—Azenta spent ~$90M on facility capex 2023–2024 to expand cold storage capacity, keeping margins pressured despite high double-digit topline growth.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 revenue ≈ $215M\u003c\/li\u003e\n\u003cli\u003e2024 growth ≈ 28%\u003c\/li\u003e\n\u003cli\u003e40+ global biorepositories\u003c\/li\u003e\n\u003cli\u003eCapex ≈ $90M (2023–2024)\u003c\/li\u003e\n\u003cli\u003ePrimary growth driver; capital-intensive\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Consumables for Automated Workflows\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eProprietary tubes, racks, and sealing tech for automation are driving fast adoption as labs shift from manual workflows; Azenta reported 22% revenue growth in consumables in 2024, tied to automated system installs.\u003c\/p\u003e\n\u003cp\u003eThe razor-and-blade model yields recurring, high-margin sales—consumables gross margin exceeded 68% in FY2024—so hardware deployment boosts long-term revenue visibility.\u003c\/p\u003e\n\u003cp\u003eAzenta leads via sample integrity and tracking innovations (real-time RFID, cryo-stable seals), holding roughly 35% market share in automated consumables as of Q4 2024, sustaining a durable competitive edge.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e22% consumables revenue growth in 2024\u003c\/li\u003e\n\u003cli\u003e68%+ consumables gross margin FY2024\u003c\/li\u003e\n\u003cli\u003e35% market share in automated consumables Q4 2024\u003c\/li\u003e\n\u003cli\u003eRFID and cryo-stable seals key differentiators\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAzenta hits $1.1B: NGS, biobanking \u0026amp; consumables drive double-digit growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAzenta’s Stars: NGS, multiomics, biobanking, and consumables drove FY2024 combined revenue ≈ $1.1B with high-growth rates (NGS +18%, biobanking +28%, consumables +22%); FY2024 R\u0026amp;D $65M, capex 2023–24 $90M, NGS market share ~25%, consumables share ~35%, cryo storage share 35–40% (2024–2025).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024 value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue (stars)\u003c\/td\u003e\n\u003ctd\u003e$1.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNGS rev\u003c\/td\u003e\n\u003ctd\u003e$420M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiobanking rev\u003c\/td\u003e\n\u003ctd\u003e$215M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsumables GM\u003c\/td\u003e\n\u003ctd\u003e68%+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eComprehensive BCG Matrix assessment of Azenta’s products with strategic recommendations per quadrant—invest, hold, or divest.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page Azenta BCG Matrix placing each business unit in a quadrant for rapid strategic decisions\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSanger Sequencing Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSanger sequencing services are a mature, industry-standard method for routine verification and small-scale research; Azenta held ~35–40% share of the global capillary sequencing market in 2024, keeping volumes steady year-over-year.\u003c\/p\u003e\n\u003cp\u003eThese services need minimal incremental capex and R\u0026amp;D, yielding high gross margins—Azenta reported segment-level gross margins above 55% in FY2024—producing predictable cash flow. \u003c\/p\u003e\n\u003cp\u003eAzenta channels this free cash into higher-growth NGS (next-generation sequencing) and cell therapy lines, funding about 20–25% of annual strategic investment in 2024 and supporting its 2025 pipeline expansion. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStandard Ultra-Low Temperature Freezers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eStandard ultra-low temperature (ULT) freezers are a cash cow for Azenta, with decades-old customer ties and a reputation for reliability; Azenta held roughly 12–15% share of the global -80°C ULT market in 2024 (estimate), securing stable revenue of about $120–150M annually from non-automated units.\u003c\/p\u003e\n\u003cp\u003eMarket growth for stand-alone ULTs is ~1–3% CAGR through 2028, so marketing spend stays low while retrofit and service margins reach 25–35%; predictable 7–12 year replacement cycles in academic and clinical labs drive steady unit demand worldwide.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMaintenance and Professional Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe service contracts tied to Azenta’s installed base of automated sample-management systems generated roughly $185 million in recurring revenue in 2024, delivering gross margins above 60% and low incremental overhead.\u003c\/p\u003e\n\u003cp\u003eAs the market matured, services became the company’s primary profit source, contributing about 45% of 2024 operating income while stabilizing cash flow against volatile capital-equipment orders.\u003c\/p\u003e\n\u003cp\u003eThese maintenance and professional services boost retention—Azenta reports \u0026gt;85% contract renewal rates—and provide steady EBITDA that cushions sales cycles and funds R\u0026amp;D.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCore Sample Sourcing and Procurement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAzenta’s Core Sample Sourcing and Procurement is a mature, low-growth cash cow: in 2025 this unit supplies \u0026gt;60% of recurring sample revenue and reports mid-30s gross margins, driven by long-term client contracts and high retention.\u003c\/p\u003e\n\u003cp\u003eThe market is stable—efficiency and reliability beat rapid innovation—so free cash flow funds Azenta’s digital and AI sample-intelligence R\u0026amp;D, which received $25–30M in 2024–25.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStable market, low growth\u003c\/li\u003e\n\u003cli\u003e\u0026gt;60% recurring sample revenue\u003c\/li\u003e\n\u003cli\u003eMid-30s gross margins\u003c\/li\u003e\n\u003cli\u003e$25–30M funding to AI tools (2024–25)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStandard Sample Storage Consumables\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eStandard sample storage consumables—generic labware and traditional storage tubes—are mature, high-volume products for Azenta, delivering strong economies of scale and steady margins; Azenta reported ~$120M in sample storage consumables revenue in FY2024, ~18% of company revenue.\u003c\/p\u003e\n\u003cp\u003eMarket growth is slow but steady (~3–5% CAGR 2023–2028 for lab consumables), driven by broad life-science expansion rather than disruption, so these items provide predictable cash generation and fund R\u0026amp;D and growth areas.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh volume, low margin but steady gross margins (~28% in 2024)\u003c\/li\u003e\n\u003cli\u003eFY2024 revenue ~120M, ~18% of Azenta total\u003c\/li\u003e\n\u003cli\u003eMarket CAGR ~3–5% (2023–2028)\u003c\/li\u003e\n\u003cli\u003eGlobal demand from routine lab ops ensures recurring orders\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAzenta’s high-margin cash cows: Sanger, ULT, services, samples \u0026amp; consumables\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAzenta’s cash cows—Sanger sequencing, ULT freezers, service contracts, sample sourcing, and consumables—generated stable, high-margin cash in 2024: Sanger 35–40% market share; segment gross margins \u0026gt;55%; ULT revenue $120–150M (12–15% share); services recurring revenue ~$185M, gross margin \u0026gt;60%; sample sourcing \u0026gt;60% recurring, mid-30s margins; consumables ~$120M, ~18% revenue.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eUnit\u003c\/th\u003e\n\u003cth\u003e2024 key\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSanger\u003c\/td\u003e\n\u003ctd\u003e35–40% share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eULT\u003c\/td\u003e\n\u003ctd\u003e$120–150M, 12–15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eServices\u003c\/td\u003e\n\u003ctd\u003e$185M, \u0026gt;60% GM\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsumables\u003c\/td\u003e\n\u003ctd\u003e$120M, ~18% rev\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eDelivered as Shown\u003c\/span\u003e\u003cbr\u003eAzenta BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing on this page is the final Azenta BCG Matrix you'll receive after purchase—no watermarks, no placeholder content—just a fully formatted, analysis-ready report designed for strategic clarity and professional presentation. This preview is identical to the downloadable document, crafted with market-backed insights and ready for editing, printing, or immediate sharing with stakeholders. After purchase, the complete file is delivered directly to your inbox for instant use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56748182634873,"sku":"azenta-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/azenta-bcg-matrix.png?v=1772205807","url":"https:\/\/matrixbcg.com\/products\/azenta-bcg-matrix","provider":"MatrixBCG","version":"1.0","type":"link"}